Literature DB >> 30563981

Severe dyspnea caused by rapid enlargement of cervical lymph node in a relapsed/refractory B-cell lymphoma patient following chimeric antigen receptor T-cell therapy.

Aiyun Jin1,2,3, Jingjing Feng1,2,3, Zhudan Wang1,2,3, Li Jiang1,2,3, Yongxian Hu1,2,3, Kui Zhao4, He Huang5,6,7.   

Abstract

Adoptive transfer of T cells modified to express chimeric antigen receptors (CARs) targeting CD19 (CART19s) has demonstrated impressive results in treating B-cell malignancies. Although CART19-induced complications have been gradually recognized, local cytokine-release syndrome (CRS) at particular parts of the body has not been extensively studied. In this paper, we firstly present a successfully treated case of severe dyspnea caused by the rapid enlargement of cervical lymph node following CART19 therapy in a relapsed/refractory DLBCL patient, with emphasis on the recognition, workup, and treatment. This report reminds for a careful evaluation and observation of the pre-existing mass, which could enlarge rapidly again as a result of CRS and be life threatening, in the CART therapy.

Entities:  

Year:  2018        PMID: 30563981     DOI: 10.1038/s41409-018-0412-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma.

Authors:  Houli Zhao; Yiyun Wang; Elaine Tan Su Yin; Kui Zhao; Yongxian Hu; He Huang
Journal:  Front Med       Date:  2020-12-01       Impact factor: 4.592

Review 2.  The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma.

Authors:  Jianshu Wei; Yang Liu; Chunmeng Wang; Yajing Zhang; Chuan Tong; Guanghai Dai; Wei Wang; John E J Rasko; J Joseph Melenhorst; Wenbin Qian; Aibin Liang; Weidong Han
Journal:  Signal Transduct Target Ther       Date:  2020-07-29

3.  Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy.

Authors:  Lei Qiu; Feng Zhu; Guoqing Wei; Wenjun Wu; Luxin Yang; Yongxian Hu; He Huang
Journal:  Regen Ther       Date:  2020-05-15       Impact factor: 3.419

4.  Factors Associated with Costs in Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies.

Authors:  Feng Zhu; Guoqing Wei; Mingming Zhang; Houli Zhao; Wenjun Wu; Luxin Yang; Yongxian Hu; He Huang
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

5.  Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia.

Authors:  Haruko Shima; Takumi Kurosawa; Hiroyuki Oikawa; Hisato Kobayashi; Emiri Nishi; Fumito Yamazaki; Kentaro Tomita; Hiroyuki Shimada
Journal:  Case Rep Oncol       Date:  2022-03-15

Review 6.  Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective.

Authors:  Chengxin Luan; Junjie Zhou; Haixia Wang; Xiaoyu Ma; Zhangbiao Long; Xin Cheng; Xiaowen Chen; Zhenqi Huang; Dagan Zhang; Ruixiang Xia; Jian Ge
Journal:  Front Immunol       Date:  2021-07-19       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.